原发性肝癌疼痛患者四种给药方法的成本-效果分析

Abstract
Figure/Table
References (15)
Related Citation (0)

Download: PDF (0 KB) HTML (28 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo compare cost effectiveness by Morphine sulfate sustained-release tablets,Oxycodone hydrochloride prolonged-release tablets,Fentanyl transdermal patches and Buprenorphine transdermal patches in the treatment of primary hepatic carcinoma pain.MethodsFrom April 2015 to April 2017,100 patients with pain of primary liver cancer were selected and randomly divided into four groups(A,B,C and D)according to different administration methods,with 25 cases in each group.Group a was given Morphine sulfate sustained release tablets,group B was given oxycodone hydrochloride sustained release tablets,group C was given Fentanyl transdermal patch,group D was given buprenorphine transdermal patch.After treatment for 30 days,the efficacy,adverse reactions and quality of life of the four groups were observed,and cost-effectiveness analysis was carried out.ResultsGroup B and C had higher analgesic effect than group A and D.There was no significant difference in the analgesic effect between the four groups(P＞0.05).there was no significant difference in the incidence of adverse reactions between the four groups after 1 month of drug use (P＞0.05).A-mong them,the adverse reactions in group B(Oxycodone hydrochloride sustained release tablets group)were less.There was significant difference between the four groups before and after treatment(P＜0.001),but there was no significant difference between the four groups(P=0.059).After two-to-two comparison of the four groups,it was found that there was significant difference between group A and group B(P=0.026),group B and group D(P=0.031),the quality of life among the other groups improved,there was no significant difference(P＞0.05);BC/E＜AC/E＜CC/E＜DC/E,there was no significant difference in the efficiency of cost-effect analysis among the four groups(P＞0.05).ConclusionThere were no significant differences in the effective rate of treatment by using four drugs.Compared the adversereactions and quality of life,the oxycodone hydrochloride prolonged-release tablets was the best schedule in the treatment of primary hepatic carcinoma pain from pharmaconomics.

Key words： Morphine sulfate sustained-release tablets Oxycodone hydrochl oride prolonged-release tablets Fentanyl transdermal patches Buprenorphine transdermal patches Primary hepatic carcinoma Pharmaconomics Cost effectiveness analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAI Yan-jin

Cite this article:

LAI Yan-jin. Cost effectiveness analysis of fourmedications for primary hepatic carcinoma pain[J]. 中国当代医药, 2018, 25(4): 150-152.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I4/150

[1]	樊松,彭丽华,漆兴之.癌性疼痛控制现状分析[J].中国中医药资讯，2010，2（14）：104-105.
[2]	张晓霞，陈慧蓉，刘月琴.癌痛控制的现状及建议[J].解放军护理杂志，2006，23（10）：54-56.
[3]	关红漫,安刚.癌性疼痛处理指南[J].临床麻醉学杂志，2005，21（5）：361-363.
[4]	周永刚，蓝晓红.癌性疼痛规范化治疗的原则与进展[J].中国医院用药评价与分析，2012，12（8）：763-765.
[5]	周进，卢俊，石莉，等.癌性疼痛规范化治疗共识解读[J].中国医刊，2015，50（9）：18-22.
[6]	陈杉，冉瑞智.三阶梯止痛疗法治疗晚期癌症疼痛的临床应用[J].湖北民族学院学报，2010，27（1）：69-70.
[7]	NCCN Clinical Practice Guidelines in Oncology-Acute Lymphoblastic Leukemia（2016 Version I）[DB/OL].http://www.nccn.org.
[8]	谭诚炜.三阶梯镇痛简介及其应用现况[J].上海医药，2015，36（2）：46-48.
[9]	闫冠韫，吴延丽，程伟.从吗啡的研究历程看阿片类镇痛药物的发展与应用[J].黑龙江医药，2014，27（6）：1325-1328.
[10]	姜小琴.药物经济学在临床用药决策中的应用[J].中国现代医生，2011，49（9）：111-112.
[11]	林伟光.充分发挥药物经济学在药品费用控制中的作用[J].医学理论与实践，2009，22(7)：880-881.
[12]	李明晖，李洪超，马爱霞.我国药物经济学评价研究的现状、问题及建议[J].中国药房，2008，19（11）：801-805.
[13]	刘晶煜，胥萍，李文娟.硫酸吗啡控释片和芬太尼透皮贴剂治疗癌痛经济学评价[J].中国药师，2011，14（5）：703-704.
[14]	李湘辉，李翠兵，周晓峰.四种阿片类镇痛药用于癌性疼痛治疗的药物经济学评价[J].现代肿瘤医学，2013，21（1）：169-171.
[15]	江再茂，位争伟,李瑛.加替沙星序贯疗法治疗泌尿系统感染的成本-效果分析[J].中国药房，2007，18（23）：1767-1768.